[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammaging":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,89,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100651481","the-effects-of-quercefit-and-ubiqsome-in-mitigating-inflammation-and-promoting-metabolic-health-100651481",false,"NCT07760506","The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health","The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Males and females aged 50 to 75 years\n* Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).\n* BMI of \\> or equal to 25.00kg\u002Fm²\n* Individuals with \\> or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https:\u002F\u002Fwww.cdc.gov\u002Fprediabetes\u002Ftakethetest)\n* Free of all other chronic diseases.\n* Not currently using glucose-lowering agents or insulin.\n* Able to read and write in English\n* Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.\n* During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.\n* During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements\n* Willing to have blood drawn\n* Must have access to a reliable internet connection and a computer to complete remote assessments\n\nExclusion Criteria:\n\n* Unwilling to have blood drawn\n* Unwilling to swallow pills\n* Pregnancy or has breast fed within 3 months prior to enrollment\n* Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months\n* Current use of Quercetine or CoQ10 supplements within the past 4-weeks\n* History or current alcohol or drug abuse\n* Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.\n* Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B\u002FC, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment\n* Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and\u002For ability to follow study subject requirements and\u002For record the necessary study measurements.\n* History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)\n* History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)\n* History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)\n* History of kidney or liver disease\n* History of metabolic disorders (diabetes, metabolic syndrome, other)\n* History of current malignancy\u002Fcancer\n* Receiving chemotherapy agents or radiation treatments\n* Diagnosis of a terminal illness\n* The investigator feels that, for any reason, the subject is not eligible to participate in the study",true,"ALL","50 Years","75 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.\n\nThe main questions it aims to answer are:\n\n1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo?\n2. What side effects, if any, do participants have while taking these supplements?\n\nResearchers will compare Quercefit® (500 mg\u002Fday), Ubiqsome™ (300 mg\u002Fday), and a placebo (a look-alike capsule with no active ingredient).\n\nParticipants will:\n\n1. Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks\n2. Go to a preferred clinic at the start and end of the study for a fasting blood draw\n\n   Complete at-home tests:\n3. Grip strength testing (using a device mailed to them)\n4. Online surveys about fatigue and quality of life\n5. Report any side effects and keep track of supplement use",[28,29,30,31,32],"Healthy Aging","Inflammaging","Metabolic Health","Quercetin","Coenzyme Q10",[28,29,30,34,35,36,37,38,39,40],"Blood testing","Pre-Diabetic","Composite Inflammaging Metric","Blood Glucose Regulation","Neuromuscular Function","Fatigue Impact Scale","Quality of life","NOT_YET_RECRUITING","2026-08-10",{"date":44,"type":45},"2026-08-12","ACTUAL",{"date":47,"type":22},"2026-08",{"date":49,"type":22},"2028-08",{"name":51,"class":52},"Applied Science & Performance Institute","INDUSTRY",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":53},"100638771","agewise-unravelling-the-gut-hormone-axis-in-womens-ageing-100638771","NCT07614542","AGEWISE: Unravelling the Gut-Hormone Axis in Women's Ageing","Inclusion Criteria:\n\n* Female sex\n* Aged 40 to 64 years\n* Resident in mainland Portugal or the islands\n* Able and willing to provide written informed consent\n* Willing to provide stool and blood samples and complete three questionnaires\n\nExclusion Criteria:\n\n* Age below 40 years or 65 years and older\n* Inability to give informed consent\n* Refusal to provide stool or blood samples or complete questionnaires\n* Pregnancy\n* Diagnosed gastrointestinal disorders (including inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, chronic diarrhoea of unknown cause, or recurrent Clostridioides difficile infection)\n* Active oncological disease","FEMALE","40 Years","64 Years",{"count":64,"type":22},300,"OBSERVATIONAL","AGEWISE is an observational study that aims to understand how changes in gut microbiome are related to hormonal changes during women's ageing, particularly across the different stages of menopause. The study will include healthy women aged 40 to 64 years living in Portugal, who will provide stool and blood samples and complete questionnaires about their health, lifestyle, diet, and menopausal symptoms. Researchers will study the gut microbiome together with hormone levels and markers of inflammation to better understand how menopause affects long-term health and to support the development of improved prevention strategies for women.",[68,69,70,71,29],"Menopause","Gut Microbiome","Hormonal Changes","Chronic Low-Grade Inflammation",[73,74,75,76,77],"microbiome","biomarkers","metagenomics","menopausal transition","women's health","RECRUITING","2026-05-22",{"date":81,"type":45},"2026-05-29",{"date":83,"type":45},"2025-06-02",{"date":85,"type":22},"2036-12",{"name":87,"class":88},"Gulbenkian Institute for Molecular Medicine","OTHER",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":16,"sex":17,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":53},"100623383","resveratrol-effects-on-inflammatory-biomarkers-and-cardiometabolic-parameters-100623383","NCT07395921","Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.","Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults. (RESINCA-trial)","RESINCA","Inclusion Criteria:\n\n* Comunnity-dwelling persons.\n* Any ethnicity.\n* With willingness to consume the bar daily during the intervention period.\n\nExclusion Criteria:\n\n* Allergy\u002Fintolerance to ingredients in the bar.\n* Pregnancy or breastfeeding.\n* Use of antioxidant\u002Fpolymeroid supplements in the last 4 weeks.\n* Unstable chronic diseases (e.g., severe liver failure, advanced kidney failure, active cancer).\n* Persons in treatments that strongly interfere with polyphenol metabolism (e.g., antibiotics, anti-inflammatories, corticosteroids, anti-allergy medication).\n* Persons with metal prosthesis.\n* Persons undergoing or waiting for metabolic bariatric surgery.\n* Persons with scheduled digestive surgery within the next 8 weeks\n* Persons in recent treatments for hypertension (less than 3 month).\n* Participation in another clinical trial.","18 Years","65 Years",{"count":100,"type":22},75,[25],"This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults",[104,105,106,107,29],"Inflammation Biomarkers","Cardiometabolic Health Indicators","Antioxidant Status, Inflammation","Antioxidant Capabilities",[109,110,111,112,113,114],"Resveratrol","inflammation","inflammaging","antioxidant","cardiometabolic health","nutritional intervention","2026-05-18",{"date":117,"type":45},"2026-05-19",{"date":119,"type":22},"2026-06-01",{"date":121,"type":22},"2026-12-01",{"name":123,"class":52},"Center for Research and Innovation Viña Concha y Toro",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":132,"targetDuration":133,"studyType":65,"phases":4,"briefSummary":134,"conditions":135,"keywords":142,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":53},"100621576","macrophagemonocyte-driven-inflammation-and-anesthetic-sensitivity-in-aging-100621576","NCT07372417","Macrophage\u002FMonocyte Driven Inflammation and Anesthetic Sensitivity in Aging","Role of Macrophage\u002FMonocyte Mediated Inflammatory Response in Diminished Anesthetic Requirements During Aging","MACRO-AGE","Inclusion Criteria:\n\n* Age between 18-30 years or over 60 years old\n* Scheduled for abdominal surgery\n* General anesthesia planned with or without spinal anesthesia\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Chemotherapy or systemic corticosteroid use within the past 2 weeks.\n* Pregnancy.\n* Active sepsis or systemic infection.\n* Emergency surgery.\n* Requirement of ketamine or dexmedetomidine during the first hour of anesthesia.\n* History or diagnosis of: stroke with persistent neurological deficit, dementia, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, central nervous system autoimmune disorders, systemic autoimmune diseases, or infectious diseases of the central nervous system.\n* Current treatment with immunomodulatory medications.\n* Psychiatric disorders with psychotic features.\n* Use of psychoactive or psychotropic recreational drugs within the week prior to surgery.",{"count":21,"type":22},"1 Day","The goal of this observational study is to determine whether macrophage\u002Fmonocyte mediated inflammatory signaling contributes to reduced anesthetic requirements in older adults undergoing major abdominal surgery. The main questions it aims to answer are:\n\n* Is there a difference in anesthetic dosing requirements (minimum effective dose) between young and older patients undergoing major abdominal surgery?\n* How do electroencephalographic (EEG) signatures under anesthesia correlate with age and systemic inflammatory markers?\n* Is there an association between age, levels of circulating inflammatory cytokines, and monocyte\u002Fmacrophage phenotypes with anesthetic requirements?\n\nIf there is a comparison group: Researchers will compare older adult patients undergoing major abdominal surgery to younger adult patients undergoing major abdominal surgery to see if macrophage\u002Fmonocyte-mediated inflammatory signaling influences anesthetic sensitivity and the risk of postoperative neurocognitive complications in the older population.\n\nParticipants will:\n\n* Receive general anesthesia for major abdominal surgery, with continuous recording of anesthetic dose requirements.\n* Undergo electroencephalographic (EEG) monitoring during the anesthetic period.\n* Provide blood samples for the measurement of circulating inflammatory cytokines and the assessment of monocyte phenotypes.\n* Provide peritoneal tissue samples (collected during surgery) to evaluate tissue macrophage populations.\n* Provide cerebrospinal fluid (CSF) samples to assess biomarkers of blood-brain barrier permeability.",[136,137,138,139,140,104,29,141],"Aging","Inflammation","Blood-Brain Barrier Permeability","Anesthesia Brain Monitor","Anesthesia Depth Monitoring","Monocyte",[136,137,143,144,145,146,147,148,149],"General Anesthesia","Anesthetic Sensitivity","Cytokines","Alpha Oscillations","Blood Brain Barrier","Monocyte phenotype","macrophage phenotype","2026-01-19",{"date":152,"type":45},"2026-01-28",{"date":154,"type":22},"2026-01-25",{"date":156,"type":22},"2027-06-15",{"name":158,"class":88},"University of Chile"]